PRAS40 regulates protein synthesis and cell cycle in C2C12 myoblasts.
PRAS40 is an mTOR binding protein that has complex effects on cell metabolism. Our study tests the hypothesis that PRAS40 knockdown (KD) in C2C12 myocytes will increase protein synthesis via upregulation of the mTOR-S6K1 pathway. PRAS40 KD was achieved using lentiviruses to deliver short hairpin (sh)-RNA targeting PRAS40 or a scrambled control. C2C12 cells were used as either myoblasts or differentiated to myotubes. Knockdown reduced PRAS40 mRNA and protein content by >80% of time-matched control values but did not alter the phosphorylation of mTOR substrates, 4E-BP1 or S6K1, in neither myoblasts nor myotubes. No change in protein synthesis in myotubes was detected, as measured by the incorporation of (35)S-methionine. In contrast, protein synthesis was reduced 25% in myoblasts. PRAS40 KD in myoblasts also decreased proliferation rate with an increased percent of cells retained in the G1 phase. PRAS40 KD myoblasts were larger in diameter and had a decreased rate of myotube formation as assessed by myosin heavy chain content. Immunoblotting revealed a 25-30% decrease in total p21 and S807/811 phosphorylated Rb protein considered critical for G1 to S phase progression. Reduction in protein synthesis was not due to increased apoptosis, since cleaved caspase-3 and DNA laddering did not differ between groups. In contrast, the protein content of LC3B-II was decreased by 30% in the PRAS40 KD myoblasts, suggesting a decreased rate of autophagy. Our results suggest that a reduction in PRAS40 specifically impairs myoblast protein synthesis, cell cycle, proliferation and differentiation to myotubes.
Kazi
Abid A
AA
Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA. akazi@hmc.psu.edu
Lang
Charles H
CH
D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001343:Autophagy / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D048429:Cell Size / Q000187:drug effects; D055785:Gene Knockdown Techniques; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D051379:Mice; D024510:Muscle Development / Q000187:drug effects; D018485:Muscle Fibers, Skeletal / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D032446:Myoblasts / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*; D018995:Myosin Heavy Chains / Q000378:metabolism; D010750:Phosphoproteins / Q000378:metabolism*; D014176:Protein Biosynthesis / Q000187:drug effects; D034741:RNA, Small Interfering / Q000378:metabolism; D012265:Ribonucleotides / Q000494:pharmacology
D010750:Phosphoproteins; D034741:RNA, Small Interfering; D012265:Ribonucleotides; C508191:proline-rich Akt substrate, 40 kDa protein, mouse; D000620:Aminoimidazole Carboxamide; D007334:Insulin-Like Growth Factor I; D018995:Myosin Heavy Chains; C031143:AICA ribonucleotide
Am J Physiol Cell Physiol. 2009 Jun;296(6):C1248-57
19357234
PLoS One. 2007 Nov 21;2(11):e1217
18030348
Nat Cell Biol. 2007 Mar;9(3):316-23
17277771
Genes Dev. 2004 Aug 15;18(16):1926-45
15314020
Genes Dev. 1999 Jan 15;13(2):213-24
9925645
Exp Cell Res. 1993 Jul;207(1):163-70
8391462
J Biol Chem. 2003 Mar 21;278(12):10189-94
12524439
Cell Signal. 2009 Jun;21(6):827-35
19166929
Mol Cell Biol. 2004 Jan;24(1):200-16
14673156
Biochem Biophys Res Commun. 2001 Sep 21;287(2):562-7
11554766
Autophagy. 2008 May;4(4):524-6
18367868
Science. 1995 Feb 17;267(5200):1024-7
7863329
Int J Cancer. 2010 Mar 1;126(5):1144-54
19688827
Nature. 2006 May 25;441(7092):424-30
16724053
Transplant Proc. 2008 Dec;40(10 Suppl):S5-8
19100909
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Aug;17(4):870-3
19698219
Proc Int Conf Intell Syst Mol Biol. 1996;4:68-77
8877506
Nutr Cancer. 2003;46(2):179-85
14690794
Am J Physiol Endocrinol Metab. 2009 Aug;297(2):E304-14
19491292
J Biol Chem. 2007 Aug 24;282(34):24514-24
17604271
Cells Tissues Organs. 2009;189(1-4):88-92
18703865
Cell. 1995 Aug 25;82(4):675-84
7664346
Genes Dev. 2002 Jun 15;16(12):1472-87
12080086
Am J Physiol Endocrinol Metab. 2003 Dec;285(6):E1205-15
12944322
Cell. 2000 Oct 13;103(2):253-62
11057898
Mol Cell. 2007 Mar 23;25(6):903-15
17386266
Cell. 2002 Jul 26;110(2):163-75
12150925
Alcohol Clin Exp Res. 2008 May;32(5):796-805
18336631
Curr Top Microbiol Immunol. 2004;279:169-97
14560958
Am J Physiol Endocrinol Metab. 2009 Oct;297(4):E935-40
19654287
Anticancer Res. 2009 Aug;29(8):3087-94
19661320
Nat Genet. 2004 Jun;36(6):585-95
15146184
Am J Physiol Endocrinol Metab. 2005 Dec;289(6):E969-80
16046454
Int J Oncol. 2009 Feb;34(2):581-9
19148495
Endocrinology. 1997 Oct;138(10):4153-9
9322924
J Biol Chem. 2007 Feb 9;282(6):3702-12
17164244
J Biol Chem. 2008 Jun 6;283(23):15619-27
18372248
Cell Signal. 2008 Apr;20(4):659-65
18207367
J Nutr. 2006 Jan;136(1 Suppl):227S-31S
16365087
Am J Physiol Endocrinol Metab. 2006 Jul;291(1):E80-9
16760336
J Biol Chem. 2007 Jul 13;282(28):20329-39
17517883
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13796-801
11707573
Cell. 2009 May 29;137(5):873-86
19446321
Am J Physiol Endocrinol Metab. 2002 May;282(5):E1092-101
11934675
FEBS Lett. 2010 Apr 2;584(7):1287-95
20083114
Hum Mol Genet. 2009 Sep 1;18(17):3298-310
19505958
Cell. 2005 Nov 18;123(4):569-80
16286006
Am J Physiol Cell Physiol. 2003 Nov;285(5):C1019-27
12826599
Cancer Res. 2007 Apr 15;67(8):3626-36
17440074
Cardiovasc Hematol Agents Med Chem. 2009 Jan;7(1):52-63
19149544
Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1555-67
17264220